Evidence map›Paper›PMID 36395524›Full record

ArticleThe neuroradiology journal2023

Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.

Abdulaziz Alshehri, Oun Al-Iedani, Nikitas Koussis, Ibrahim Khormi, Rodney Lea, Jeannette Lechner-Scott, Saadallah Ramadan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The neuroradiology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdulaziz AlshehriSchool of Health Sciences, University of Newcastle College of Health, Medicine and Wellbeing, Callaghan, NSW, Australia.ORCID 0000-0003-4893-223X
Oun Al-IedaniHunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Nikitas KoussisHunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Ibrahim KhormiSchool of Health Sciences, University of Newcastle College of Health, Medicine and Wellbeing, Callaghan, NSW, Australia.
Rodney LeaHunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Jeannette Lechner-ScottHunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Saadallah RamadanSchool of Health Sciences, University of Newcastle College of Health, Medicine and Wellbeing, Callaghan, NSW, Australia.ORCID 0000-0003-3874-7866

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeDiffusion MRI (dMRI) is sensitive to microstructural changes in white matter of people with relapse-remitting multiple sclerosis (pw-RRMS) that lead to progressive disability. The role of diffusion in assessing the efficacy of different therapies requires more investigation. This study aimed to evaluate selected dMRI metrics in normal-appearing white matter and white matter-lesion in pw-RRMS and healthy controls longitudinally and compare the effect of therapies given. MATERIAL AND

methodsStructural and dMRI scans were acquired from 78 pw-RRMS (29 injectables, 36 fingolimod, 13 dimethyl fumarate) and 43 HCs at baseline and 2-years follow-up. Changes in dMRI metrics and correlation with clinical parameters were evaluated.

resultsDifferences were observed in most clinical parameters between pw-RRMS and HCs at both timepoints (

conclusionsThis is the first DTI study comparing the effect of different treatments on dMRI parameters over time in a stable cohort of pw-RRMS. The results suggest that brain microstructural changes in a stable MS cohort are similar to HCs independent of the therapies used.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingWhite MatterBrainDimethyl FumarateFingolimod HydrochlorideHumansDimethyl FumarateFingolimod HydrochlorideClinical parametersDiffusion tensor imaging (DTI)disease-modifying therapies (DMTs)Multiple Sclerosis (MS)White Matter (WM)

Identifiers

PMID36395524
PMCPMC10588600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.